Market Place
Market Place
Post Enquiry
FDA approvals slump 19% in H1 2024; NASH, COPD, PAH get new treatment options
The first half of 2024 saw a significant slowdown in approvals of new drugs and biologics by the US
FDA approvals rise 49% in 2023; CRISPR’s gene editing therapy sees light of day
In 2022, when the
US Food and Drug Administration (FDA) was reeling under the impact of the
pandem
